AbbVie claims FTC is sitting on key pay-for-delay documents; Sanofi's Cerdelga performs in new JAMA study; GSK's Arixtra beats heparin in heart attacks;

@FiercePharma: Call me Allergan, Actavis says. The buyer will take $AGN's name after their marriage. Release | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Shanghai official linked to $GSK bribery sentenced to 19 years in prison. Article | Follow @CarlyHFierce

> The Federal Trade Commission is holding back key documents in a pay-for-delay case over the testosterone drug Androgel, say AbbVie ($ABBV) and fellow defendants Actavis ($ACT), Par Pharmaceutical and Paddock Laboratories. Report

> Sanofi's ($SNY) Cerdelga beat placebo in Gaucher disease patients by several measures, including spleen and liver volume, hemoglobin levels and platelet counts, according to a randomized clinical trial published in the Journal of the American Medical Association. Release | Report

> GlaxoSmithKline's ($GSK) clot-fighter Arixtra (fondaparinux) topped heparin at treating a particular type of heart attack, according to a Swedish study published by the Journal of the American Medical Association. Report

> Florida's top court called a halt to executions until the U.S. Supreme Court decides whether using a particular anesthetic constitutes "cruel and unusual" punishment. Report

> People who boosted their dosages of opioid drugs to deal with chronic pain were more likely to see an increase in depression, a study in the journal Pain showed. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: MRI-guided radiation startup files to raise up to $69M in IPO. Article | Follow @FierceMedDev

@VarunSaxena2: FDA agrees to review Pfizer's abuse-deterring opioid candidate. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: Can Eisai pump its thyroid cancer pill to $1B in sales? Rival Bayer might object. FiercePharmaMarketing article | Follow @EmilyWFierce

> Artificial heart sees most patients to donor heart within a few years. More

> Boston Scientific hands over $600M to settle breach-of-contract Guidant suit with J&J. Article

> Owens & Minor on CEO search ... again. Report

Biotech News

@FierceBiotech: Can Actavis deliver a promised $6B boost from this pipeline? More | Follow @FierceBiotech

@JohnCFierce: Heard it on the biotech grapevine? Drop me a line. Editor's corner | Follow @JohnCFierce

@DamianFierce: Does anyone know what the "F" in F. Michael Ball stands for? $HSP weirdly won't tell us. | Follow @DamianFierce

> Eagle soars as Teva steps up with $120M pact for a rival to Treanda franchise. Article

> Inotek slashes share price ahead of IPO. Item

> Apotex targets Amgen's blockbuster with latest biosimilar app. More

> Star scientist Peter Mueller gets $28M war chest to advance R&D at Pronutria. Story

> Sanofi beefs up its autoimmune pipeline with a biotech deal. Report

Drug Delivery News

> Lupin inks two partnerships to bring lung drugs to overseas markets. Report

> Developer of oral versions of biologic therapies to be purchased by Intrexon. Item

> Actavis divests its drug delivery unit as it barrels toward acquisition of Allergan. News

> Genzyme touts postmarket study of Cerdelga, the only first-line oral therapy for Gaucher disease. Story

> FDA agrees to review Pfizer's abuse-deterring opioid candidate. Article

Diagnostics News

> Lancet study finds that Qiagen's Quantiferon estimates lower rate of TB in China than the traditional test. Story

> Myriad Genetics resolves patent battle with GeneDx over BRCA technology. Item

> Dako joins up with Ono to develop cancer companion Dx. News

> Israel's Pocared receives $15M in funding to commercialize bacteria-identifying computer. Report

> ACT Genomics ropes in $8M for cancer molecular Dx in first private funding round. Article

Pharma Marketing News

> Can Eisai pump its thyroid cancer pill to $1B in sales? Rival Bayer might object. Story

> Fed-up MD Anderson oncologist jumps on social media to fight drug prices. More

> AstraZeneca picks outspoken (and sometimes critical) prof to join board. Story

> To Pfizer's Chantix, a new JAMA study sounds like 14M potential patients. Article

> AstraZeneca's Pulmicort gets temporary reprieve as judge halts generics launch. Report

> And Finally... Doctors overestimate their patients' use of prescribed drugs, a survey finds; physicians believe less than 10% don't stick to their regimens, when in reality, more than 15% of patients fall short. Report

Suggested Articles

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.

Already developing coronavirus treatments, Takeda struck a licensing deal to manufacture and market Novavax's vaccine candidate in Japan

Pfizer struck a deal to produce Gilead Sciences' remdesivir, which has been running short at some hard-hit U.S. hospitals.